Medpace Q2 2026 shows strong new business and backlog, but valuation remains high.
Medpace Holdings reported strong Q2 2026 results with a net book-to-bill ratio of 1.13x and a $3.0 billion backlog, driven by robust oncology bookings despite a decline in cardiometabolic awards. Management expects a normalization of business mix ove...
